2. [A] The peptide factor [as] of [claimed in C] claim 1, wherein the N terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety, the C terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety or a murine epidermal growth factor cysteine residue thiol group is chemically modified by the addition of an amino acid capping moiety to the cysteine residue thiol group. [wherein the peptide factor is further modified by at least one modification chosen selected from the group comprising consisting of capping the N terminal of the peptide, capping the C terminal of the peptide and capping thiol groups of cysteine.]

3. [A] The peptide factor [as] of [claimed in C] claim 1 [or 2], wherein the murine epidermal growth factor tyrosine residue [tyrosine] is substituted by [Tic-OH] tetrahydroisoquinoline-3-carboxylic acid.

4. [A] The peptide factor [as] of [claimed in C] claim 1 [,2 or 3], wherein the murine epidermal growth factor arginine residue [arginine] is substituted by Citrulline.

5. A method of binding a laminin receptor as an antagonist comprising preparing [Use of a peptide factor as claimed in any of the preceding claims in the preparation of] a medicament [to bind laminin receptors as an antagonist] comprising amino acid residues 33 to 42 of murine epidermal growth factor peptide wherein the peptide factor is modified such that at least one murine epidermal growth factor tyrosine amino acid residue is substituted with a tyrosine analogue or at least one murine epidermal growth factor arginine amino acid residue is substituted with an arginine analogue.

6. A method of binding a laminin receptor as an agonist comprising preparing [Use of a peptide factor as claimed in any of the preceding claims in the preparation of] a medicament [to bind laminin receptors as an antagonist] comprising amino acid residues 33 to 42 of murine

epidermal growth factor peptide wherein the peptide factor is modified such that at least one murine epidermal growth factor tyrosine amino acid residue is substituted with a tyrosine analogue or at least one murine epidermal growth factor arginine amino acid residue is substituted with an arginine analogue.

7. [Use as claimed in] The method of claim 6, wherein [in] the preparation of [a] the medicament to bind a laminin receptor as an antagonist is used to treat [for healing] endothelial cell wounding.

8. [Use as claimed in claim 8 or 9] The method of claim 5, wherein [for] the medicament to bind a laminin receptor as an antagonist is used to treat[ment of] retinopathy of immaturity.

Please add the following claims 9-18:

--9. The peptide factor of claim 2, wherein the murine epidermal growth factor tyrosine residue is substituted by tetrahydroisoquinoline-3-carboxylic acid. --

--10. The peptide factor of claim 2, wherein the murine epidermal growth factor arginine residue is substituted by Citrulline. --

--11. The peptide factor of claim 2, wherein the murine epidermal growth factor arginine residue is substituted by Citrulline. --

--12. The method of claim 5, wherein the N terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety, the C terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety or a murine epidermal growth factor cysteine residue thiol group is chemically modified by the addition of an amino acid capping moiety to the cysteine residue thiol group. --

--13. The peptide factor of claim 12, wherein the murine epidermal growth factor tyrosine residue is substituted by tetrahydroisoquinoline-3-carboxylic acid. --

--14. The peptide factor of claim 12, wherein the murine epidermal growth factor arginine residue is substituted by Citrulline. --

--15. The method of claim 6, wherein the N terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety, the C terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety or a murine epidermal growth factor cysteine residue thiol group is chemically modified by the addition of an amino acid capping moiety to the cysteine residue thiol group. --

--16. The peptide factor of claim 15, wherein the murine epidermal growth factor tyrosine residue is substituted by tetrahydroisoquinoline-3-carboxylic acid. --

--17. The peptide factor of claim 15, wherein the murine epidermal growth factor arginine residue is substituted by Citrulline. --

--18. The method of claim 6, wherein the medicament to bind a laminin receptor as an agonist is used to treat retinopathy of immaturity. --

REMARKS

Upon entry of the foregoing amendment, claims 1-18 are pending in the application. Claims 1-3 stand rejected. Claims 4-8 stand objected to. Claims 9-18 have been added by this Amendment. No new matter has been added with those claims in that support for these amendments can be found in the original claims as filed. For example new claim 9 tracks claim 3, new claim 10 tracks claim 4, new claim 11 tracks claim 4, new claim 12 tracks claim 2, new